Archive for July, 2012

Rust Removal For Less: Rusterizer Offers Savings, Ships Rust Removal…

Rusterizer has a new special offer. The company announced that it's now shipping it's non-toxic rust removal product for free.(PRWeb July 31, 2012)Read the full story at http://www.prweb.com/releases/2012/7/prweb9744141.htm


Rust Removal For Less: Rusterizer Offers Savings, Ships Rust Removal…

Rusterizer has a new special offer. The company announced that it's now shipping it's non-toxic rust removal product for free.(PRWeb July 31, 2012)Read the full story at http://www.prweb.com/releases/2012/7/prweb9744141.htm


World Environmental & Agricultural Monitoring Wireless Sensors…

New research study “Wireless Sensors for Precision Agriculture and Environmental Monitoring – Global Forecast and Analysis by Sensor Types, Applications and Geography (2011-2016)” prepared by…(PRWeb July 30, 2012)Read the full story at http://…


AMRESCO Offers New RiboReady™ Color RNA Ladders for Easy Band…

Easily estimate RNA molecular weight and confirm RNA transfer from gel to membrane with AMRESCO’s new RiboReady™ Color RNA Ladders.(PRWeb July 30, 2012)Read the full story at http://www.prweb.com/releases/2012/7/prweb9744179.htm


Drug Patent Expirations for Jul 15 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for July 15 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
RESCULA Sucampo
Pharms
unoprostone isopropyl 5,221,763 Jul 15,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Continue reading

Drug Patent Expirations for Jul 26 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for July 26 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
MULTAQ Sanofi Aventis
Us
dronedarone hydrochloride 5,223,510 Jul 26,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Share this:


Continue reading